Clinical Trial Update: SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial SGN-00101 was investigated for preventing anal cancer in HIV-positive patients with anal neoplasia; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer

Drugs mentioned

• SGN-00101

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anal Cancer | Phase 1, Phase 2 | Status: COMPLETED